STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

EXCLUSIVE: Harmony Biosciences’ CEO, Jeffrey Dayno, on Innovation and Expanding Patient Impact

byLiliana Vida
October 29, 2024
in Biotechnology, Q&A's, Small-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Stoxpo: Harmony Biosciences has shown strong growth with WAKIX. What factors are behind this performance?

Jeffrey Dayno: Our growth is rooted in our commitment to addressing significant unmet needs in neuroscience. WAKIX, as a non-scheduled treatment for excessive daytime sleepiness in adults with narcolepsy, stands out in the market due to its unique mechanism of action. We’ve dedicated significant resources to expanding access, raising awareness, and supporting both patients and healthcare providers, which has strengthened WAKIX’s presence. Additionally, ongoing post-marketing studies and our exploration of WAKIX’s potential in other indications will allow us to help a broader patient community.

Stoxpo: Beyond WAKIX, what’s in Harmony’s pipeline that investors and patients should keep an eye on?

Jeffrey Dayno: We’re especially excited about HBS-102, a drug targeting the melanin-concentrating hormone receptor pathway, which plays a critical role in sleep and other neurological functions. It’s still early in its development, but we see strong promise in HBS-102’s potential to treat additional rare neurological disorders. We’re also continuously looking for partnerships and acquisitions that align with our mission to expand and enhance our portfolio.

Stoxpo: You’ve focused on rare neurological diseases. Do you see further expansion into other areas?

Jeffrey Dayno: While we remain centered on neuroscience and rare, underserved conditions, we’re always open to exploring adjacent opportunities where we can create meaningful impact. With neurological disorders on the rise, particularly those like narcolepsy and central nervous system disorders, we see room for innovation. We plan to stay focused but flexible, building a diverse pipeline that supports patients, caregivers, and the medical community.

Stoxpo: How does Harmony plan to sustain growth and remain competitive?

Jeffrey Dayno: Our strategy is rooted in innovation and patient support. We’re committed to investing in R&D, expanding our commercial reach, and enhancing educational resources for patients and providers. Real-world data helps us refine our approach with WAKIX and sets the foundation for future products. We balance organic growth with strategic M&A to diversify our portfolio and strengthen our position in the market.

Stoxpo: The narcolepsy treatment landscape has seen growth. What sets Harmony apart?

Jeffrey Dayno: Harmony is dedicated to providing safe, effective, and non-scheduled treatment options for narcolepsy. WAKIX’s novel mechanism of action has established it as a trusted treatment in the community. Our focus isn’t only on treating symptoms but also on enhancing quality of life. By consistently seeking feedback from the narcolepsy community, we can address real needs and reinforce WAKIX’s role in narcolepsy care.

Stoxpo: What challenges does Harmony face, and how are you addressing them?

Jeffrey Dayno: One challenge is adapting to potential changes in regulatory standards and market dynamics. To navigate this, we’re expanding our clinical research efforts, engaging proactively with regulatory bodies, and building a robust internal infrastructure. As our pipeline grows, staying focused and rigorous in both development and commercialization is essential to our continued growth and impact.

Stoxpo: How does Harmony’s commitment to patient access factor into its long-term vision?

Jeffrey Dayno: Access is fundamental to Harmony’s mission. We’ve developed programs to assist patients with treatment costs and offer resources to healthcare providers to ease access barriers. Our ultimate aim is to build trust and establish Harmony as a reliable partner to patients, caregivers, and the broader medical community, making meaningful strides in neurological treatment options.

Previous Post

American Airlines in Talks with Citigroup for Exclusive Credit Card Deal

Next Post

Report Says Qualcomm Eyes Intel in Potential Takeover Bid

Related Posts

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

byLiliana Vida
November 18, 2026
0

New KULR ONE Max order strengthens the company's energy storage portfolio, with deliveries scheduled through 2027. KULR Technology Group (NYSE:...

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

byLuca Blaumann
November 10, 2026
0

Company reports $7.4 million in quarterly revenue, exits Bitcoin holdings, and strengthens its balance sheet with $54.5 million in cash...

Next Post

Report Says Qualcomm Eyes Intel in Potential Takeover Bid

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.